Jounce Therapeutics — Investor Presentation (April 2020)
28 slides from Jounce Therapeutics's investor presentation, Apr 7, 2020
Slide 1: Jounce Therapeutics: A Next Gen Immunotherapy Company
Exhibit 99.1 Jounce Therapeutics A Next Gen Immunotherapy Company April 2020
Slide 2: Legal Disclaimer
Legal Disclaimer Various statements concerning our future expectations, plans and prospects, including without limitation, our expectations regarding the timing, progress and results of discovery programs, preclinical studies and clinical trials for our product candidates and any future product cand
Slide 3: The Jounce Difference
The Jounce Difference Clinical Stage IO Pipeline • Vopratelimab: ICOS Agonist in Phase 2 – Two development paths, guided by clinical data and biomarkers – EMERGE preliminary efficacy data in 2H20 – SELECT initiation mid-year 2020 • JTX-4014: Phase 2 ready PD-1 Inhibitor (PD-1i) – First use in combo
Slide 4: The Core of Our Approach: Translational Science Platform
The Core of Our Approach: Translational Science Platform Translational Drug Discovery Reverse Translational Analysis • Sustainable engine for 1st in class • Patients with clinical outcomes • Focused on multiple immune cell • PD* and predictive biomarkers types • Patients more likely to respond *PD=
Slide 5: Jounce Immunotherapy Pipeline
Jounce Immunotherapy Pipeline Preclinical Clinical Program Target Biology Discovery IND Enabling Phase 1 Phase 2 Phase 3 Development Programs CD4 T cell Vopratelimab ICOS focused CD8 T cell JTX-4014 PD-1 focused Suppressive JTX-8064 LILRB2 macrophage Not JTX-1811 T-regulatory Disclosed Discovery Pro
Slide 6: Development Programs: Vopratelimab
Development Programs Vopratelimab JTX-4014 JTX-1811
Slide 7: ICOS Pathway May Be Key to Durable IO Response
ICOS Pathway May Be Key to Durable IO Response Resting T cells No Immune Stimulus Low Levels of ICOS Antigen Priming ICOS high CD4 T Cells CD4 T helper 1 (Th1) CD4 T follicular helper (Tfh) • Cell mediated immunity • Regulate B cells • Express cell lytic function • Maturation of antibody response •
Slide 8: Vopratelimab Harnesses CD4 T Cell Biology
Vopratelimab Harnesses CD4 T Cell Biology A Different Element of the Immune Response, Distinct from PD-1 Inhibitors Vopratelimab Stimulates ICOS hi CD4 Th1, Tfh, Tcm* • Humanized IgG1 • Selective for stimulating ICOS pathway • Safe and well tolerated • Vopra PD biomarker correlates with clinical ben
Slide 9: Vopratelimab Value Proposition
Vopratelimab Value Proposition BiologicalBiological activity activity beyond distinct CD8 from focused CD8 focused PD-1 inhibitors PD-(L)1i* Biomarker driven development paths based on clinical data KeyKey Learnings Learnings from from ICONIC** ICONIC** • Highly durable responses • Identified vopra
Slide 10: Clinical Benefit Associated with ICOS hi CD4 T Cells
Clinical Benefit Associated with ICOS hi CD4 T Cells Vopratelimab, but not PD-(L)1i, Causes Emergence of ICOS hi CD4 T Cells* Tumor Reduction Tumor Change from Baseline 100 Data cut-off 10-DEC-2019 75 As of 31-JAN-2020 All patients with evaluable samples and tumor measurement, n = 41 50 25 % Change
Slide 11: ICOS hi CD4 T Cells: Characteristics Suggest Involvement in Anti-tumor Response
ICOS hi CD4 T Cells: Characteristics Suggest Involvement in Anti-tumor Response ICOS hi CD4 T cells express Th1 transcription factor ICOS hi CD4 T Cells Characteristics T bet, and do not express T regulatory markers CD3+CD4+ CD3+CD4+ICOS+ Cytotoxic Function Effector T cell Activation (Log2) Memory F
Slide 12: Clinical Benefit Associated with ICOS hi CD4 T Cells
Clinical Benefit Associated with ICOS hi CD4 T Cells ICONIC Clinical Benefit: ICOS hi vs. ICOS lo CD4 T Cells* ICOS hi (n=20) ICOS lo (n=24) RECIST 1.1 ORR 4 (20.0%) 0 Median PFS 6.2 months 2.0 months Median OS 20.7 months 9.0 months Progression Free Survival Overall Survival As of 31-JAN-2020 As of
Slide 13: Reverse Translational Work Leads to Two Development Paths
Reverse Translational Work Leads to Two Development Paths EMERGEEMERGE SELECT Hypothesis: Inducer Combinations Hypothesis: Predictive Biomarker Prioritize combinations with agents Select patients with TISvopra, optimized to that induce ICOS hi CD4 T cells predict for ICOS hi CD4 T cell emergence CTL
Slide 14: EMERGE: Phase 2 Vopratelimab Combo with Ipilimumab
EMERGE: Phase 2 Vopratelimab Combo with Ipilimumab Phase 2 EMERGE Study – Initiated June 2019 • PD-(L)1i experienced NSCLC – high unmet need – Standard of Care: docetaxel – Two 20 patient dose cohorts – Endpoints: ORR, DCR, DOR, PFS, OS, safety – Enrollment on track for clinical and biomarker data i
Slide 15: SELECT: Phase 2 Predictive Biomarker Study
SELECT: Phase 2 Predictive Biomarker Study Phase 2 SELECT Randomized Study • IO naïve 2L NSCLC in ~75 patients (ex-US) • Patients selected with TISvopra, optimized to predict for ICOS hi CD4 T cells • Estimate ~20% of 2L NSCLC patients above biomarker cut-off • Interim clinical data expected in 2021
Slide 16: TIS Contains Genes Important for CD4 T Cell Activation
TIS Contains Genes Important for CD4 T Cell Activation Elements of TIS* TIS Biology Gene PSMB10 Antigen Presenting Cell HLA-DQA1 Abundance HLA-DRB1 CMKLR1 HLA-E T Cell / NK Cell Abundance NKG7 CD8A CCL5 CXCL9 CD27 IFN Activity CXCR6 IDO1 STAT1 TIGIT LAG3 T Cell Exhaustion CD4274 PDCD1LG2 CD276 *Dana
Slide 17: TISvopra Predicts ICOS hi CD4 T Cells and Clinical Benefit
TISvopra Predicts ICOS hi CD4 T Cells and Clinical Benefit TISvopra Predicts Emergence of ICOS hi CD4 T Cells TISvopra Predicts Overall Survival ICONIC Patients with Longitudinal T Cells Available and Overall Survival: Baseline Tumor RNA ICONIC Patients with Baseline Tumor RNA PPV = 89% NPV = 78% Ab
Slide 18: Unique Dosing Strategy for EMERGE and SELECT
Unique Dosing Strategy for EMERGE and100 SELECT t 80 n e saturation of receptor m e g 60 a g Pulsatile Dosing of Vopra May Be Preferable n Lowersa tDosesuration of s igMaynaling Optimize Profile E 40 t e g r a 20 0.03 mg/kg vopra + ipi T 100 • Target engagement internalizes ICOS % 100 Dose0. 1used m
Slide 19: NSCLC Significant Market Opportunity
NSCLC Significant Market Opportunity NSCLC PD-(L)1i Experienced (EMERGE) • Growing patient population with unmet need (estimate over 40,000 patients*) – Majority of frontline non-driver mutation patients in US treated with PD-(L)1i regimen • Docetaxel is current SoC for platinum and PD-(L)1i experie
Slide 20: Development Programs: JTX-4014
Development Programs Vopratelimab JTX-4014 JTX-1811
Slide 21: JTX-4014: Phase 2 Ready PD-1 Inhibitor
JTX-4014: Phase 2 Ready PD-1 Inhibitor Well-Characterized PD-1 Antibody, Fully Human IgG4 Target Lesion Change from Baseline Over Time Phase 1 Study Results* • Late stage IO naïve patients, median 4.5 Data cut-off 21-FEB-2020 lines of prior therapy • No deaths or dose limiting toxicities • 3/18 (16.
Slide 22: Development Programs: JTX-1811
Development Programs Vopratelimab JTX-4014 JTX-1811
Slide 23: JTX-1811: Designed to Deplete Immunosuppressive T regulatory Cells
JTX-1811: Designed to Deplete Immunosuppressive T regulatory Cells • T regulatory cells (T regs) • JTX-1811 is a monoclonal – Diminish productive immune responses antibody designed to deplete – Immune response to tumors may require T regs in the tumor reducing T regulatory effect microenvironment JT
Slide 24: Single Agent Anti-Tumor Activity in PD-1 Inhibitor Resistant Tumors
Single Agent Anti-Tumor Activity in PD-1 Inhibitor Resistant Tumors Also Restores PD-1i Activity PD-1 Inhibitor Resistant Mouse Tumor Models Selective Depletion of Tumor T regs Colon-26 Tumor MBT-2 Tumor Tumor Resident Immunosuppressive T regs 5/10 complete responder 5/9 complete JTX-1811 responder
Slide 25: The Jounce Approach: Sustainable Discovery for 1st in Class Immunotherapies
The Jounce Approach: Sustainable Discovery for 1st in Class Immunotherapies Translational Science Platform Innovative & Sustainable Discovery Pipeline Immunosuppressive T regulatory cells New target ID from 1000s of human tumors Inhibit immunosuppressive activity Stromal cells Approach for cold tumo
Slide 26: Financial Strength and Flexibility
Financial Strength and Flexibility Financial Overview Funding History NASDAQ: JNCE Event Date Gross $ Comment Series A 2013 $47M Third Rock Strong balance sheet: Ventures • $170.4M cash and investments, Series B 2015 $56M Fidelity, as of December 31, 2019 Wellington, others Financial guidance: CELG
Slide 27: 2020 Milestones
2020 Milestones ▪ Vopratelimab: Preliminary efficacy and related biomarker data from EMERGE in 2H20 ▪ Vopratelimab + JTX-4014: SELECT study, patient selection using TISvopra, initiation mid-year ▪ JTX-1811: ▪ Presentation at a scientific meeting in 1H20 ▪ Accepted for AACR 2020 ▪ Continue IND enabli
Slide 28: Jounce Therapeutics: A Next Gen Immunotherapy Company
Jounce Therapeutics A Next Gen Immunotherapy Company
Jounce Therapeutics — Investor Presentation (April 2020) on 6ix